Camurus announces positive results from POSITANO phase 2b study of octreotide SC depot in patients with symptomatic polycystic liver disease: Lund, Sweden Thursday, June 19, 2025, ...

UK study suggests that patients with prolactinoma treated with dopamine agonists are more likely to develop impulse control disorders ...

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND ...

Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase ...